

Patrick Forde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9680956/publications.pdf>

Version: 2024-02-01

67
papers

8,503
citations

126901

33
h-index

138468

58
g-index

70
all docs

70
docs citations

70
times ranked

10729
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986. | 27.0 | 1,495 |
| 2 | Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1973-1985. | 27.0 | 871 |
| 3 | Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019, 570, 385-389. | 27.8 | 764 |
| 4 | Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 264-276. | 9.4 | 706 |
| 5 | Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). <i>Annals of Oncology</i> , 2018, 29, 1853-1860. | 1.2 | 304 |
| 6 | Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1493-1502. | 1.1 | 288 |
| 7 | Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1930-1939. | 1.1 | 282 |
| 8 | Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 916-925. | 0.8 | 257 |
| 9 | Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021, 596, 126-132. | 27.8 | 234 |
| 10 | Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1214-1225. | 0.9 | 226 |
| 11 | Epigenetic therapy inhibits metastases by disrupting premetastatic niches. <i>Nature</i> , 2020, 579, 284-290. | 27.8 | 213 |
| 12 | PD-1 Blockade in Anaplastic Thyroid Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2620-2627. | 1.6 | 177 |
| 13 | Detection and characterization of lung cancer using cell-free DNA fragmentomes. <i>Nature Communications</i> , 2021, 12, 5060. | 12.8 | 161 |
| 14 | Phase I/IIb Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spaltalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3620-3629. | 7.0 | 151 |
| 15 | Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 99-111. | 13.2 | 141 |
| 16 | Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338. | 0.9 | 140 |
| 17 | Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 553-557. | 3.4 | 119 |
| 18 | Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 914-947. | 1.1 | 119 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. <i>Cancer Immunology Research</i> , 2018, 6, 888-899. | 3.4 | 118 |
| 20 | Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160. | 7.1 | 117 |
| 21 | Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <i>Clinical Cancer Research</i> , 2017, 23, 4959-4969. | 7.0 | 115 |
| 22 | Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 494-502. | 1.1 | 114 |
| 23 | Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282. | | 108 |
| 24 | HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 314-318. | 2.0 | 103 |
| 25 | The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <i>Journal of Clinical Investigation</i> , 2019, 129, 4305-4315. | 8.2 | 100 |
| 26 | Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1327-1337. | 7.0 | 90 |
| 27 | Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e470-e479. | 2.6 | 80 |
| 28 | Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1204-1213. | 0.9 | 75 |
| 29 | Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , 2017, 22, 627-630. | 3.7 | 74 |
| 30 | A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2018, 23, 859-865. | 3.7 | 73 |
| 31 | Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. <i>Nature Medicine</i> , 2021, 27, 1910-1920. | 30.7 | 62 |
| 32 | Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. , 2018, 6, 104. | | 55 |
| 33 | Ipilimumab-induced immune-related renal failure--a case report. <i>Anticancer Research</i> , 2012, 32, 4607-8. | 1.1 | 49 |
| 34 | Use of Immune Checkpoint Inhibitors in Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 18. | 3.0 | 46 |
| 35 | Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. <i>Clinical Cancer Research</i> , 2017, 23, 4992-5002. | 7.0 | 41 |
| 36 | Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. , 2022, 10, e004688. | | 34 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Systemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2014, 9, 414-418. | 1.1 | 33 |
| 38 | Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473. | | 33 |
| 39 | Clinical mutational profiling of 1006 lung cancers by next generation sequencing. <i>Oncotarget</i> , 2017, 8, 96684-96696. | 1.8 | 32 |
| 40 | Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies. <i>Oncologist</i> , 2021, 26, e1822-e1832. | 3.7 | 31 |
| 41 | PD-1 Blockade in Early-Stage Lung Cancer. <i>Annual Review of Medicine</i> , 2019, 70, 425-435. | 12.2 | 29 |
| 42 | Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy. <i>Lung Cancer</i> , 2021, 154, 36-43. | 2.0 | 29 |
| 43 | Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 45237-45248. | 1.8 | 25 |
| 44 | Chemotherapeutic and Targeted Strategies for Locally Advanced and Metastatic Esophageal Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 673-684. | 1.1 | 21 |
| 45 | Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, . | 7.1 | 21 |
| 46 | Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. <i>Cancer Treatment Reviews</i> , 2022, 104, 102350. | 7.7 | 18 |
| 47 | Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. <i>Npj Precision Oncology</i> , 2022, 6, 13. | 5.4 | 18 |
| 48 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956. | | 16 |
| 49 | Isolated progression of metastatic lung cancer: Clinical outcomes associated with definitive radiotherapy. <i>Cancer</i> , 2020, 126, 4572-4583. | 4.1 | 13 |
| 50 | Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2405-2420. | 4.2 | 10 |
| 51 | Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram. <i>Clinical Lung Cancer</i> , 2020, 21, e622-e632. | 2.6 | 9 |
| 52 | Protocol of DREAM3R: DuRvalumab with chemotherapy as first-line treatment in advanced pleural Mesothelioma—a phase 3 randomised trial. <i>BMJ Open</i> , 2022, 12, e057663. | 1.9 | 9 |
| 53 | Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. <i>Journal of Experimental Medicine</i> , 2022, 219, . | 8.5 | 8 |
| 54 | Lung and Thymic Carcinoids. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 699-709. | 3.2 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Immunotherapy trials in mesothelioma “promising results, but don’t stop here. Nature Reviews Clinical Oncology, 2019, 16, 726-728. | 27.6 | 6 |
| 56 | Neoadjuvant nivolumab in early-stage non-small cell lung cancer (NSCLC): Five-year outcomes.. Journal of Clinical Oncology, 2022, 40, 8537-8537. | 1.6 | 6 |
| 57 | Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 1556-1558. | 1.1 | 5 |
| 58 | Moving Immunotherapy Into Early-Stage Lung Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 543-547. | 2.0 | 5 |
| 59 | Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC. Journal of Thoracic Oncology, 2022, 17, 503-509. | 1.1 | 5 |
| 60 | Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. JTO Clinical and Research Reports, 2021, 2, 100220. | 1.1 | 4 |
| 61 | Immunotherapy for mesothelioma: rationale and new approaches. Clinical Advances in Hematology and Oncology, 2020, 18, 562-572. | 0.3 | 4 |
| 62 | The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy). Blood, 2013, 122, 4629-4629. | 1.4 | 1 |
| 63 | Abstract 1617: Sex-specific genomic determinants of response to immunotherapy. , 2021, , . | | 0 |
| 64 | Venous Thromboembolism Prevention Practices Among Health Care Providers Caring for Patients Hospitalized for Hematopoietic Stem Cell Transplantation: A International Web-Based Survey. Blood, 2012, 120, 2062-2062. | 1.4 | 0 |
| 65 | DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma “A phase 3 randomized trial.. Journal of Clinical Oncology, 2022, 40, TPS8599-TPS8599. | 1.6 | 0 |
| 66 | Clinical and molecular characteristics of advanced esophageal/GEJ cancer with brain metastasis.. Journal of Clinical Oncology, 2022, 40, e16092-e16092. | 1.6 | 0 |
| 67 | Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).. Journal of Clinical Oncology, 2022, 40, TPS8598-TPS8598. | 1.6 | 0 |